Sterile injectables are essential. So is earning your trust as a dependable U.S.-based partner.

Over the past decade, Pfizer has invested more than $2 billion to modernize and expand our 6 U.S. based sterile injectables manufacturing and distribution sites. Our domestic footprint, bolstered by our global manufacturing network, produces nearly 475 million units annually for the U.S. market. This robust and resilient infrastructure enables us to respond rapidly in times of patient need. At Pfizer, our commitment to resilience is not just a talking point, it’s a core strategy—one that has earned us the prestigious Diamond Badge from the Healthcare Industry Resilience Collaborative (HIRC).1

But no one can solve this challenge alone

Join us in building a stronger, more resilient sterile injectables market.
Learn more at PfizerHospitalUS.com/supply-sustainability

Reference: 1. Data on file.